Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.

Pokaži ostale verzije (1)

Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing bre...

Bibliografski detalji
Glavni autori:	Cavazzoni, A, Bonelli, M, Fumarola, C, La Monica, S, Airoud, K, Bertoni, R, Alfieri, R, Galetti, M, Tramonti, S, Galvani, E, Harris, A, Martin, L, Andreis, D, Bottini, A, Generali, D, Petronini, P
Format:	Journal article
Jezik:	English
Izdano:	2012

Slični predmeti

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
od: Cavazzoni, A, i dr.
Izdano: (2012)

Synergistic activity of letrozole and sorafenib on breast cancer cells.
od: Bonelli, M, i dr.
Izdano: (2010)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
od: Foroni, C, i dr.
Izdano: (2009)

The identification of the mTOR-regulated phosphoproteome and a mediator of feedback inhibition to P13K-Akt
od: Hsu, Peggy Ping
Izdano: (2011)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
od: Grozinsky-Glasberg, S, i dr.
Izdano: (2008)

mTOR Signalling, Nutrients and Disease
od: Goberdhan, D, i dr.
Izdano: (2008)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
od: Generali, D, i dr.
Izdano: (2008)

Mutations in the HECT domain of NEDD4L lead to AKT-mTOR pathway deregulation and cause periventricular nodular heterotopia.
od: Broix, L, i dr.
Izdano: (2016)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
od: Fox, S, i dr.
Izdano: (2006)

mTOR Signaling in Growth Control and Disease
od: Laplante, Mathieu, i dr.
Izdano: (2014)

An emerging role of mTOR in lipid biosynthesis
od: Laplante, Mathieu, i dr.
Izdano: (2012)

mTOR Signaling in Growth, Metabolism, and Disease
od: Saxton, Robert Andrew, i dr.
Izdano: (2018)

The mTOR pathway and integrating immune regulation.
od: Cobbold, S
Izdano: (2013)

The effects of mTOR inhibition in ischemic stroke
od: Schneider, AM
Izdano: (2022)

Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
od: Dworakowska, D, i dr.
Izdano: (2009)

A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses
od: Bent, Eric H, i dr.
Izdano: (2017)

Influenza vaccines: mTOR inhibition surprisingly leads to protection.
od: Mcmichael, A, i dr.
Izdano: (2013)

The TSC-mTOR pathway regulates macrophage polarization
od: Byles, Vanessa, i dr.
Izdano: (2015)

A Central Role for mTOR in Lipid Homeostasis
od: Lamming, Dudley W., i dr.
Izdano: (2016)

mTOR at the nexus of nutrition, growth, ageing and disease
od: Liu, Grace Y, i dr.
Izdano: (2021)

mTOR and cancer: many loops in one pathway
od: Efeyan, Alejo, i dr.
Izdano: (2012)

mTOR signalling and metabolic regulation of T cell differentiation.
od: Peter, C, i dr.
Izdano: (2010)

mTOR signalling and the regulation of Hoxp3 expression
od: Peter, C
Izdano: (2013)

Resistance mechanisms to mTOR inhibition in renal cancer
od: Earwaker, P
Izdano: (2015)

mTOR regulates memory CD8 T-cell differentiation.
od: Araki, K, i dr.
Izdano: (2009)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
od: Carbonneau, M, i dr.
Izdano: (2016)

Effects of albumin–chlorogenic acid nanoparticles on apoptosis and PI3K/Akt/mTOR pathway inhibitory activity in MDA-MB-435s cells
od: Alzahrani, Badr, i dr.
Izdano: (2023)

Insights into the regulation of mTOR signaling and the consequences of pharmacological inhibition
od: Thoreen, Carson Cornell
Izdano: (2009)

Reversal of phenotypes of cellular senescence by pan-mTOR inhibition
od: Cox, L, i dr.
Izdano: (2016)

Amino acid sensing and mTOR regulation: inside or out?
od: Goberdhan, D, i dr.
Izdano: (2009)

The role of tryptophan and the mTOR pathway in T cell fate determination
od: Karydis, I, i dr.
Izdano: (2014)

Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease.
od: Yates, S, i dr.
Izdano: (2013)

Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia
od: Hadley, G, i dr.
Izdano: (2019)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
od: Generali, D, i dr.
Izdano: (2009)

Induction of apoptosis via JNK and AKT/mTOR signaling pathways by Alternanthera sessilis (L.) R.Br. ex DC. in colorectal cancer in vitro and in vivo
od: Sivapragasam, Gothai
Izdano: (2019)

The Rapamycin Derivative RAD001 (Everolimus) Inhibits Cell Proliferation and Interacts with the Akt-mTOR-p70S6K Pathway in Human Medullary Thyroid Carcinoma Cells
od: Grozinsky-Glasberg, S, i dr.
Izdano: (2009)

Regulation of mTOR complex 1 in response to growth factors and nutrients
od: Sancak, Yasemin S. (Yasemin Shechner)
Izdano: (2010)

mTOR: from growth signal integration to cancer, diabetes and ageing
od: Zoncu, Roberto, i dr.
Izdano: (2012)

mTOR-S6K1 pathway mediates cytoophidium assembly
od: Sun, Z, i dr.
Izdano: (2019)

mTOR: dissecting regulation and mechanism of action to understand human disease.
od: Goberdhan, D, i dr.
Izdano: (2009)